{"id":"maraviroc-mvc","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL256907","moleculeType":"Small molecule","molecularWeight":"513.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Maraviroc is a selective antagonist of the CCR5 co-receptor, which HIV uses as an entry point into host cells alongside the primary CD4 receptor. By binding to CCR5, maraviroc prevents the virus from attaching to and entering CD4+ T cells, thereby blocking HIV infection. This mechanism is effective only against CCR5-tropic (R5) HIV strains, not X4-tropic variants that use the CXCR4 co-receptor.","oneSentence":"Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:56.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with CCR5-tropic virus"},{"name":"HIV-1 infection in treatment-naïve patients (in combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06974084","phase":"PHASE2, PHASE3","title":"Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).","status":"NOT_YET_RECRUITING","sponsor":"HealthBio, Inc.","startDate":"2025-09-01","conditions":"Long COVID","enrollment":252},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT04475991","phase":"PHASE2","title":"Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults","status":"TERMINATED","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2021-07-13","conditions":"COVID-19","enrollment":19},{"nctId":"NCT02519777","phase":"PHASE4","title":"Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-21","conditions":"HIV Infections","enrollment":191},{"nctId":"NCT01505114","phase":"PHASE2","title":"Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"HIV Infection","enrollment":594},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01276236","phase":"PHASE2","title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-03-09","conditions":"Kaposi's Sarcoma","enrollment":13},{"nctId":"NCT03708861","phase":"PHASE3","title":"Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients","status":"WITHDRAWN","sponsor":"University of Turin, Italy","startDate":"2016-01","conditions":"HIV Infection","enrollment":""},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT01894776","phase":"PHASE1","title":"A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-06","conditions":"HIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)","enrollment":15},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT03969550","phase":"","title":"Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2008-01","conditions":"AIDS, Progressive Multifocal Leucoencephalopathy (PML)","enrollment":34},{"nctId":"NCT00709111","phase":"NA","title":"Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-01","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT02346084","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults","status":"COMPLETED","sponsor":"International Partnership for Microbicides, Inc.","startDate":"2015-01","conditions":"HIV/AIDS","enrollment":19},{"nctId":"NCT00764465","phase":"PHASE2","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-10","conditions":"Healthy","enrollment":45},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01384682","phase":"PHASE4","title":"Maraviroc Switch Collaborative Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-08","conditions":"HIV","enrollment":399},{"nctId":"NCT01291459","phase":"PHASE2","title":"Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients","status":"UNKNOWN","sponsor":"Association Pour la Recherche en Infectiologie","startDate":"2011-09","conditions":"HIV","enrollment":40},{"nctId":"NCT02626923","phase":"","title":"Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients","status":"COMPLETED","sponsor":"Nicholaos C Bellos, MD","startDate":"2012-07","conditions":"Drug-induced Hypotension","enrollment":51},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT01719627","phase":"PHASE1","title":"First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2012-10","conditions":"HIV","enrollment":10},{"nctId":"NCT01330199","phase":"PHASE1","title":"Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-02","conditions":"Healthy Adult Females","enrollment":49},{"nctId":"NCT00884858","phase":"PHASE4","title":"Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2009-04","conditions":"HIV Infections","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Selzentry"],"phase":"marketed","status":"active","brandName":"Maraviroc (MVC)","genericName":"Maraviroc (MVC)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus, HIV-1 infection in treatment-naïve patients (in combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}